公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study | Langer C.J; Gadgeel S.M; Borghaei H; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG ; Gubens M; Sequist L.V; Awad M.M; Fiore J; Ge Y; Raftopoulos H; Gandhi L; KEYNOTE-021 investigators | The Lancet Oncology | 1168 | 1066 | |
2018 | Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study | Gadgeel S.M; Stevenson J.P; Langer C.J; Gandhi L; Borghaei H; Patnaik A; Villaruz L.C; Gubens M; Hauke R; CHIH-HSIN YANG ; Sequist L.V; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V. | Lung Cancer | 69 | 60 | |
2019 | Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation | CHIH-HSIN YANG ; Gadgeel S.M; Sequist L.V; Wu C.-L; Papadimitrakopoulou V.A; Su W.-C; Fiore J; Saraf S; Raftopoulos H; Patnaik A. | Journal of Thoracic Oncology | 130 | 104 | |
2016 | Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer | Gadgeel S.M; Shaw A.T; Govindan R; Gandhi L; Socinski M.A; Camidge D.R; De Petris L; Kim D.-W; Chiappori A; Moro-Sibilot D.L; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; CHIH-HSIN YANG ; Han J.-Y; Bordogna W; Golding S; Zeaiter A; Ou S.-H.I. | Journal of Clinical Oncology | 163 | 142 | |
2020 | Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer | Ou S.-H.I; Gadgeel S.M; Barlesi F; CHIH-HSIN YANG ; De Petris L; Kim D.-W; Govindan R; Dingemans A.-M; Crino L; Léna H; Popat S; Ahn J.S; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos P.N; Shaw A.T. | Lung Cancer | 23 | 10 |